BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 01, 2013
 |  BioCentury  |  Emerging Company Profile

XO1: Bleed-free anticoagulation

XO1's ichorcumab may provide anticoagulation without risk of bleeding

Marketed anticoagulants including warfarin and antiplatelet therapies are used to prevent thrombosis, but they also have dose-dependent increases in the risk of major bleeding. XO1 Ltd. is developing a mAb targeting an allosteric site on thrombin that has the potential to provide anticoagulation without increasing the risk of bleeding.

"Researchers were generally resigned to the fact that it would likely be impossible to dissociate anticoagulation from bleeding risk," said XO1 CEO and Index Venture Partner David Grainger. But a chance clinical observation paired with corroborating in vivodata suggests XO1's ichorcumab might be able to separate the two effects.

Hematologists and XO1 scientific co-founders Trevor Baglin and James Huntington discovered ichorcumab after Baglin saw a patient complaining of headache at Cambridge University Hospitals' Addenbrooke's Hospital. Huntington is professor of hematology at the University of Cambridge's Cambridge Institute for Medical Research.

After a CT scan revealed a small hematoma on the patient's brain, a coagulation screen was conducted.

"What came back...

Read the full 792 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >